Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...

In December and January, the US Food and Drug Administration (FDA) approved new therapies for lung cancer, atopic dermatitis, obstructive sleep apnea (OSA), and cystic fibrosis. The FDA also added a ...

It is a miracle drug." GLP-1 agonist drugs, like Ozempic, Wegovy, Mounjaro and Zepbound, can help with weight loss by mimicking at least one hormone produced by the gut to signal fullness ...

Sangeetha Nadarajah reports Amid the rising popularity of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.

Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to step up from Zepbound's (GLP-1 drug from LLY ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...